ClinicalTrials.gg
TerminatedNCT04829331Updated Apr 18, 2023Results posted

Utility of Restrata With Split Thickness Skin Graft to Reconstruct the Forearm Donor Site

An interventional study of Restrata in Wound Heal, sponsored by Acera Surgical, Inc.. Terminated at 1 site in United States. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2023-04-18.

Sponsored by Acera Surgical, Inc. (part of Solventum) · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Lack of clinical research staff

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
5
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

Understand association between use of Restrata (Acera Surgical Inc., St. Louis, MO) in forearm flap reconstruction with donor site healing and function

02

Conditions studied

  • Wound Heal
03

In context

Lead sponsor

Acera Surgical, Inc. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

First submitted before Acera Surgical, Inc. became part of Solventum.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. All patients age 19 or greater that will undergo radial forearm free flap or ulnar free flap.
  2. Photo documentation of wound bed at two weeks and four weeks must be obtainable either by physician or patient.

Exclusion criteria

Exclusion Criteria:

  1. Active systemic (active use of high-dose (≥40mg prednisone daily or equivalent) or other immunosuppressive medications OR medical conditions causing immunosuppression, i.e. etc).
  2. Diabetes mellitus with most recent ≥10.0 within 30 days prior to surgery.
  3. Morbid obesity ( >40).
  4. Inability to maintain wrist immobilization for full planned period.
  5. Severe malnutrition (prealbumin levels \<10 mg per dL within 30 days prior to surgery OR BMI \<15 (very severely underweight).
  6. Other conditions felt to significantly impair wound healing per surgeon discretion.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Restrata with a split-thickness skin graft

    Device: Restrata

  • No intervention
    Split-thickness skin graft alone

Interventions

  • DeviceRestrata

    Restrata is a sterile, single use device intended for use in local management of wounds

06

What researchers measure

Primary outcomes

  1. Tendon Exposure

    Percentage of participants with tendon exposure

    Time frame: 4 weeks post-operatively

  2. Surface Area of Split-thickness Skin Graft Incorporation

    Percentage of surface area of split-thickness skin graft incorporation

    Time frame: 4 weeks post-operatively

07

Results

Posted Apr 18, 2023

Participant flow

Participant flow — Overall Study
MilestoneRestrata With a Split-thickness Skin GraftSplit-thickness Skin Graft Alone
Started32
Completed22
Not completed10
Withdrew: Lost to follow-up10

Outcome measures

PrimaryTendon Exposure

Percentage of participants with tendon exposure

Time frame:
4 weeks post-operatively
Reported as:
Count of participants · Participants
Tendon Exposure
ParticipantsRestrata With a Split-thickness Skin GraftSplit-thickness Skin Graft Alone
% of patients with tendon exposure at 4 weeks10
% patients lost to follow up prior to 4 weeks10
% of patients with tendon coverage at 4 weeks12
PrimarySurface Area of Split-thickness Skin Graft Incorporation

Percentage of surface area of split-thickness skin graft incorporation

Time frame:
4 weeks post-operatively
Reported as:
Count of participants · Participants
Surface Area of Split-thickness Skin Graft Incorporation
ParticipantsRestrata With a Split-thickness Skin GraftSplit-thickness Skin Graft Alone
90% graft take01
% not assessed due to study termination31

Adverse events

Collected over 4 weeks after skin graft harvest. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Restrata With a Split-thickness Skin Graft0/3 (0%)1/3 (33.3%)0/3 (0%)
Split-thickness Skin Graft Alone0/2 (0%)0/2 (0%)0/2 (0%)
Most frequent serious events
Most frequent serious events
EventRestrata With a Split-thickness Skin GraftSplit-thickness Skin Graft Alone
InfectionSkin and subcutaneous tissue disorders1/30/2

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Restrata With a Split-thickness Skin GraftSplit-thickness Skin Graft AloneTotal
<=18 years000
Between 18 and 65 years123
>=65 years202
Age, Continuous
Age, Continuous(years)Restrata With a Split-thickness Skin GraftSplit-thickness Skin Graft AloneTotal
Mean69.3 ± 4.549.5 ± 5.561.4 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)Restrata With a Split-thickness Skin GraftSplit-thickness Skin Graft AloneTotal
Female000
Male325
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Restrata With a Split-thickness Skin GraftSplit-thickness Skin Graft AloneTotal
Hispanic or Latino000
Not Hispanic or Latino325
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Restrata With a Split-thickness Skin GraftSplit-thickness Skin Graft AloneTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White325
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Restrata With a Split-thickness Skin GraftSplit-thickness Skin Graft AloneTotal
United States325
08

Study locations

1 site
  • Nebraska Methodist Hospital
    Omaha, Nebraska 68114, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2021 to primary completion in Jan 2022, 8 months.

Results were first posted in Apr 2023, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2021
First posted
Apr 2, 2021
StartActual
Apr 9, 2021
Primary completionActual
Jan 1, 2022
CompletionActual
Jan 1, 2022
Results first posted
Apr 18, 2023
Last update
Apr 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04829331
Responsible party
Sponsor
First posted
Apr 2, 2021
Start date
Apr 9, 2021
Primary completion
Jan 1, 2022
Completion
Jan 1, 2022
Results posted
Apr 18, 2023
Last update
Apr 18, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion